Merit Medical Systems, Inc.

Report azionario NasdaqGS:MMSI

Capitalizzazione di mercato: US$4.8b

Merit Medical Systems Crescita futura

Criteri Future verificati 1/6

Merit Medical Systems prevede che gli utili e i ricavi cresceranno rispettivamente di 12.6% e 5.7% all'anno. Si prevede che l'EPS crescerà di 11.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 12.6% in 3 anni.

Informazioni chiave

12.6%

Tasso di crescita degli utili

11.36%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili16.5%
Tasso di crescita dei ricavi5.7%
Rendimento futuro del capitale proprio12.63%
Copertura analitica

Good

Ultimo aggiornamento14 Jul 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento narrativa • Jul 03

MMSI: Lower P/E Assumptions Will Set Up Future Repricing Potential

The analyst price target for Merit Medical Systems has been reduced from about $118 to $110 as analysts incorporate a slightly lower assumed future P/E multiple, while maintaining modestly higher revenue growth and profit margin assumptions. Analyst Commentary Recent Street research on Merit Medical Systems has centered on lower price targets, but many reports still highlight constructive views on the company’s execution and long term opportunity set.
Aggiornamento narrativa • Jun 19

MMSI: Discount Rate Reset And 2026 Guidance Will Support Share Price

Analysts have trimmed their price targets on Merit Medical Systems by between $2 and $20, with the updated fair value estimate holding near $89.55 as they adjust assumptions around discount rates and valuation multiples while keeping revenue growth and profit margin expectations broadly unchanged. Analyst Commentary Recent Street research around Merit Medical Systems shows a cluster of reduced price targets, but the commentary behind those changes is more mixed.
Aggiornamento narrativa • Jun 04

MMSI: Margin Strength And 2026 Guidance Reset Will Drive Future Upside

Merit Medical Systems' analyst price target has been reset lower by about $8.82 per share. This change reflects analysts' updated assumptions for slightly softer revenue growth, a modestly lower discount rate, stronger profit margins, and a reduced future P/E multiple.
Nuova narrativa • May 16

Oncology And Endoscopy Platforms Will Reshape Long Term Earnings Power

Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?
Seeking Alpha • May 02

Merit Medical Systems: Creating More Growth Engines (Rating Upgrade)

Summary Merit Medical Systems trades at 17-18x earnings with solid fundamentals, moderate leverage, and reasonable valuation, supporting an upbeat outlook. Q1 organic growth was on the lower end, but full-year guidance was maintained and even slightly raised for sales, reflecting recent M&A contributions. Growth engines include the View Point Medical acquisition and WRAPSODY, both expected to accelerate revenue and margin expansion into 2026. Despite softer organic growth and CEO transition, Merit's business remains resilient, with potential for re-rating as growth drivers materialize. Read the full article on Seeking Alpha
Nuova narrativa • May 01

Tariffs And OEM Volatility Will Pressure Margins Yet Long Term Procedure Demand Will Support Progress

Catalysts About Merit Medical Systems Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide. What are the underlying business or industry changes driving this perspective?
Aggiornamento narrativa • Apr 24

MMSI: 2026 Guidance Execution And Margin Resilience Will Drive Future Upside

Analysts have nudged their price targets on Merit Medical slightly lower, with the updated fair value estimate moving from about $101.18 to $98.36 as they factor in modestly softer profit margin assumptions and a somewhat higher future P/E multiple, alongside recent target cuts and a downgrade tied to 2026 guidance uncertainty. Analyst Commentary Recent research on Merit Medical Systems highlights a mix of confidence in the business model and caution around execution against medium term targets, especially the 2026 outlook.
Aggiornamento narrativa • Apr 08

MMSI: 2026 Margin Outlook And Guidance Will Drive Upside Potential

Analysts have trimmed the blended fair value estimate for Merit Medical Systems to about $101 from roughly $104, reflecting a lower projected price target that incorporates higher discount rates, slightly softer revenue growth assumptions, and a more moderate future P/E multiple, even as margin expectations improve. Analyst Commentary Recent Street research on Merit Medical Systems presents a mixed picture, with some analysts trimming targets or ratings on guidance uncertainty, while others still see room for valuation support based on execution and margins.
Articolo di analisi • Dec 31

We Like These Underlying Return On Capital Trends At Merit Medical Systems (NASDAQ:MMSI)

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Seeking Alpha • Mar 16

Merit Medical: A Success Story That Keeps Getting Better

Summary Merit Medical continues to outperform, with the share price supported by on-target financial results, incremental M&A, and positive clinical data. The company's Wrapsody stent graft showed almost best-case clinical efficacy, positioning it to capture significant market share in dialysis graft occlusion procedures. Recent acquisitions, including EsophyX Z+ and Cook Medical’s lead management portfolio, enhance Merit’s product portfolio and offer longer-term synergies. CEO succession remains a concern, but could also prompt a bid for the company. Despite not being "super cheap", Merit’s strong execution, revenue growth, and margin leverage justify a positive rating, with potential for further valuation uplift. Read the full article on Seeking Alpha
Seeking Alpha • Jan 08

Merit Medical Systems: Solid Execution, Stretched Valuations

Summary Merit Medical Systems' stock is up 40% from last spring's lows, driven by strong Q3 results and positive analyst sentiment. The stock's rally has stalled recently. The company has also made a small acquisition in September and garnered a key FDA approval to close out 2024 on a high note. More upside ahead, or will the shares experience further profit-taking?  An analysis of Merit Medical Systems follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Sep 17

Merit Medical Systems - Impressive Momentum

Summary Merit Medical Systems has shown strong operating momentum this year, driven by organic growth and strategic acquisitions. Founder Fred Lampropoulos plans to retire by the end of 2025, as a well-planned succession alleviates concerns on that front. Recent acquisitions, including EndoGastric Solutions and Cook's Medical portfolio, enhance product offerings but are priced into the current high valuation. Despite positive momentum and trial results, the stock's high valuation warrants a cautious, wait-and-see approach. Read the full article on Seeking Alpha

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:MMSI - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20281,8162092653297
12/31/20271,71818624828810
12/31/20261,62016021928810
3/31/20261,542139217297N/A
12/31/20251,516128213297N/A
9/30/20251,477118204268N/A
6/30/20251,433119190240N/A
3/31/20251,388122178225N/A
12/31/20241,357120183221N/A
9/30/20241,326120173214N/A
6/30/20241,301117177218N/A
3/31/20241,283102131167N/A
12/31/20231,25794108145N/A
9/30/20231,22610068111N/A
6/30/20231,198904595N/A
3/31/20231,1738565117N/A
12/31/20221,1517566114N/A
9/30/20221,1366289132N/A
6/30/20221,1165887122N/A
3/31/20221,1014890124N/A
12/31/20211,07548116147N/A
9/30/20211,05443105138N/A
6/30/20211,03128133168N/A
3/31/20219694131172N/A
12/31/2020964-10116165N/A
9/30/2020964-2996155N/A
6/30/2020963-3044115N/A
3/31/20201,000-41693N/A
12/31/20199955N/A78N/A
9/30/201997019N/A75N/A
6/30/201994939N/A87N/A
3/31/201991843N/A92N/A
12/31/201888342N/A87N/A
9/30/201884040N/A82N/A
6/30/201879819N/A63N/A
3/31/201876018N/A55N/A
12/31/201772828N/A63N/A
9/30/201769528N/A61N/A
6/30/201767233N/A63N/A
3/31/201763731N/A57N/A
12/31/201660420N/A54N/A
9/30/201658019N/A49N/A
6/30/201655923N/A55N/A
3/31/201654623N/A62N/A
12/31/201554224N/A69N/A
9/30/201553726N/A79N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di MMSI ( 12.6% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di MMSI ( 12.6% all'anno) cresceranno più lentamente rispetto al mercato US ( 16.7% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di MMSI cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di MMSI ( 5.7% all'anno) crescerà più lentamente rispetto al mercato US ( 12.4% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di MMSI ( 5.7% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di MMSI sarà basso tra 3 anni ( 12.6 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/07/30 08:05
Prezzo dell'azione a fine giornata2026/07/30 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Merit Medical Systems, Inc. è coperta da 22 analisti. 10 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
null nullBaird
David RescottBaird
Michael PetuskyBarrington Research Associates, Inc.